tradingkey.logo
tradingkey.logo
Search

Illumina Inc

ILMN
Add to Watchlist
181.100USD
+4.550+2.58%
Close 06/29, 16:00ETQuotes delayed by 15 min
27.53BMarket Cap
32.71P/E TTM

Illumina Inc

181.100
+4.550+2.58%
View Detailed Chart
TradingKey 图表
Intraday
1m
30m
1h
D
W
M
D

Today

+2.58%

5 Days

+12.22%

1 Month

+11.13%

6 Months

+34.67%

Year to Date

+38.08%

1 Year

+91.05%

Key Figures
177.740Open
181.280High
1.51MVolume
32.71P/E TTM
30.23P/E Dynamic
--Dividend TTM
0.99%Turnover Ratio
176.550Prev. Close
175.130Low
223.13MTurnover
LossP/E Static
10.29P/B
0.00%Div Yield TTM
13.39%ROA
158.79052wk High
0.65Volume Ratio
-1.22BNet Profit
152.00MShares
5.5358EPS TTM
1.49Beta
33.82%ROE
78.79052wk Low
3.48%Amplitude
66.09%Gross Margin
27.53BMarket Cap
3.28Reward/Risk
2.54%Risk Rate

TradingKey Stock Score of Illumina Inc

Currency: USD Updated: 2026-06-26

Key Insights

Illumina Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 15 out of 203 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 148.96.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Illumina Inc's Score

Industry at a Glance

Industry Ranking
15 / 203
Overall Ranking
58 / 4566
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Positive+

Illumina Inc Highlights

StrengthsRisks
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 31.89, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 162.52M shares, decreasing 8.64% quarter-over-quarter.
Held by Catherine Wood
Star Investor Catherine Wood holds 927.08K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.09.

Analyst Rating

Based on 22 analysts
Buy
Current Rating
148.961
Target Price
-15.63%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Illumina Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Illumina Inc Info

Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
Ticker SymbolILMN
CompanyIllumina Inc
CEOThaysen (Jacob)
Websitehttps://www.illumina.com

FAQs

What is the current price of Illumina Inc (ILMN)?

The current price of Illumina Inc (ILMN) is 181.10.

What is the symbol of Illumina Inc?

The ticker symbol of Illumina Inc is ILMN.

What is the 52-week high of Illumina Inc?

The 52-week high of Illumina Inc is 158.79.

What is the 52-week low of Illumina Inc?

The 52-week low of Illumina Inc is 78.79.

What is the market capitalization of Illumina Inc?

The market capitalization of Illumina Inc is 27.53B.

Is Illumina Inc (ILMN) currently rated as Buy, Hold, or Sell?

According to analysts, Illumina Inc (ILMN) has an overall rating of Buy, with a price target of 148.96.

What is the Earnings Per Share (EPS TTM) of Illumina Inc (ILMN)?

The Earnings Per Share (EPS TTM) of Illumina Inc (ILMN) is 5.48.
KeyAI